Calamos Advisors
COLL icon

Calamos Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Calamos Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-45,339
Closed -$1.09M – 1012
2023
Q1 		$1.09M Buy
+45,339
New +$1.2M 0.01% 795
2020
Q2 		– Sell
-48,718
Closed -$795K – 719
2020
Q1 		$795K Buy
+48,718
New +$1.01M 0.01% 614

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Calamos Advisors's COLL Position: Q2 2023 in Review

Calamos Advisors sold out of Collegium Pharmaceutical (COLL) in Q2 2023, closing a stake of 45,339 shares — an estimated $1.09M sold.

Calamos Advisors first reported a position in COLL in Q1 2020 and held it in 2 quarters. The position peaked at $1.09M in Q1 2023. 178 funds tracked by Wall St. Rank hold COLL as of Q2 2023.

  • Calamos Advisors reported no remaining Collegium Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Calamos Advisors sold 45,339 Collegium Pharmaceutical shares in Q2 2023, an estimated $1.09M.
  • Calamos Advisors first reported a position in Collegium Pharmaceutical in Q1 2020 and held it in 2 quarters.
  • Calamos Advisors's Collegium Pharmaceutical position peaked at $1.09M in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2023.

Based on Calamos Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.